Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Gynecologic Oncology

• Publication date

  2006-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.YGYNO.2006.06.025PMID 16875720
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian Cancer

  2006cited by this paper
• Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon.

  2006cited by this paper
• Analysis of the treatment of ovarian cancer patients with neo-adjuvant chemotherapy--preliminary results.

  2005cited by this paper
• Neoadjuvant chemotherapy for ovarian cancer.

  2005cited by this paper
• Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma

  2005cited by this paper
• Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.

  2005influential reference
• Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer.

  2005cited by this paper
• Discordance between beliefs and recommendations of gynecologic oncologists in ovarian cancer management*

  2004cited by this paper
• Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer

  2004influential reference
• The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma

  2004cited by this paper
• Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

  2004cited by this paper
• Secondary surgical cytoreduction for advanced ovarian carcinoma.

  2004cited by this paper
• Predictive factors for irresectability in advanced ovarian cancer

  2003cited by this paper
• Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study

  2003cited by this paper
• Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors

  2003cited by this paper
• QUALITY OF LIFE IN WOMEN TREATED WITH NEOADJUVANT CHEMOTHERAPY FOR ADVANCED OVARIAN CANCER: A PROSPECTIVE LONGITUDINAL STUDY

  2003influential reference
• IMPACT OF INTERVAL DEBULKING SURGERY ON CLINICAL OUTCOME IN PRIMARY UNRESECTABLE FIGO STAGE IIIC OVARIAN CANCER PATIENTS

  2003influential reference
• Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study.

  2003cited by this paper
• The potential role of neoadjuvant chemotherapy in advanced ovarian cancer

  2003cited by this paper
• Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer.

  2003cited by this paper
• Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer.

  2003influential reference
• CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer

  2002cited by this paper
• Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma?

  2002cited by this paper
• Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study.

  2002cited by this paper
• Interval debulking surgery in advanced epithelial ovarian cancer.

  2002cited by this paper
• Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.

  2002cited by this paper
• The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer

  2002cited by this paper
• Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer.

  2002cited by this paper
• Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma

  2001influential reference
• Identification of prognostic factors in advanced epithelial ovarian carcinoma.

  2001cited by this paper
• Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival?

  2001cited by this paper
• Neoadjuvant chemotherapy for unresectable ovarian carcinoma

  2001cited by this paper
• Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma

  2001influential reference
• Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.

  2001cited by this paper
• A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography

  2000cited by this paper
• The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.

  2000cited by this paper
• Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival.

  1999influential reference
• Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.

  1998cited by this paper
• Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975‐94 and treated at the Norwegian Radium Hospital

  1998cited by this paper
• Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.

  1998influential reference
• Extensive cytoreductive surgery in advanced ovarian carcinoma.

  1997cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper
• The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.

  1995cited by this paper
• Meta-analysis comparing cisplatin total dose intensity and survival.

  1995cited by this paper
• A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary.

  1995cited by this paper
• A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary.

  1995cited by this paper
• Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer.

  1994cited by this paper
• The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.

  1994cited by this paper
• Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphaide therapy in advanced ovarian adenocarcinoma

  1994cited by this paper
• Intervention debulking surgery in advanced epithelial ovarian cancer

  1994cited by this paper
• Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma.

  1993cited by this paper
• Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma.

  1993cited by this paper
• Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?

  1992cited by this paper
• Advanced epithelial ovarian carcinoma: long-term survival experience at the community hospital.

  1992cited by this paper
• Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer.

  1991cited by this paper
• Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study.

  1991cited by this paper
• Advanced epithelial ovarian cancer: no difference in survival rate between exploratory laparotomy and inadequate debulking surgery as treatment approach before chemotherapy.

  1990cited by this paper
• A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives.

  1989cited by this paper
• The Role of Induction Chemotherapy in Inoperable Ovarian Cancer

  1989cited by this paper
• Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.

  1975cited by this paper
• Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.

  1975cited by this paper

• The Impact of the Number of Neoadjuvant Chemotherapy Cycles on Outcomes in Advanced Ovarian Cancer: A Narrative Review.

  2026cites this paper
• Survivorship in advanced ovarian cancer: a prognostic model for overall survival and risk of recurrence

  2025cites this paper
• Assessment of textbook oncologic outcome after neoadjuvant chemotherapy and interval debulking surgery for advanced ovarian cancer

  2025cites this paper
• Remote results of treatment of patients with advanced ovarian cancer after interval and delayed cytoreductive surgery: a retrospective single-center study

  2025cites this paper
• Survival Outcomes at Three Years After Primary vs Interval Debulking in Advanced Ovarian Cancer: A Retrospective Study from Hasan Sadikin Hospital (2021)

  2025cites this paper
• Continuing chemotherapy beyond 6 cycles increases the chances of complete cytoreduction surgery in patients with advanced ovarian cancer.

  2025cites this paper
• Survival after interval and delayed cytoreduction surgery in advanced ovarian cancer: a Global Gynaecological Oncology Surgical Outcomes Collaborative-Led Study (GO SOAR2).

  2025cites this paper
• Perspective on the Advances in Surgical Gynecologic Oncology

  2025cites this paper
• Trends in Surgical Outcomes and Overall Survival Among Women Undergoing Debulking Surgery for Advanced Ovarian Cancer in the U.S: Analysis of the National Cancer Database

  2025cites this paper
• Survival-Related Prognostic Factors in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy

  2025cites this paper
• The role of neoadjuvant chemotherapy in advanced-stage clear cell ovarian cancer: A GCIG multi-institutional retrospective cohort study.

  2025cites this paper
• Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer.

  2025cites this paper
• Comparison of clinical and cost outcomes between primary and interval debulking surgery in ovarian cancer.

  2025cites this paper
• Clinical value of serum tumor markers in assessing the efficacy of neoadjuvant chemotherapy in advanced ovarian cancer: single-center prospective clinical study

  2024cites this paper
• Controversies in the Surgical Management of Gynecologic Cancer: Balancing the Decision to Operate or Hesitate.

  2024cites this paper
• Oncological Outcomes in Patients with Delayed Cytoreductive Surgery During COVID Times

  2024cites this paper
• The Use of Lipid-Based Nanocarriers to Improve Ovarian Cancer Treatment: An Overview of Recent Developments.

  2024cites this paper
• Preoperative serum level of CA153 and a new model to predict the sub-optimal primary debulking surgery in patients with advanced epithelial ovarian cancer

  2024cites this paper
• Pathological PCI as a prognostic marker of survival after neoadjuvant chemotherapy in patients undergoing interval cytoreduction with or without HIPEC in FIGO stage IIIC high grade serous ovarian cancer

  2024cites this paper
• Primary cytoreductive surgery followed by chemotherapy compared to neoadjuvant chemotherapy followed by cytoreduction as a treatment for stage III and IV ovarian cancer (literature review)

  2024cites this paper
• Evaluation of Optimal Number of Neoadjuvant Chemotherapy Cycles and Cytoreductive Surgery in Women with Ovarian Cancer

  2024cites this paper
• Comparison of Neoadjuvant Chemotherapy Plus Interval Debulking Surgery and Primary Debulking Surgery in Patients with Stage III and IV Ovarian Carcinoma: A Multicenter Real Life Experience

  2023cites this paper
• Current Status and Controversies in Neoadjuvant Chemotherapy for Advanced Stage Ovarian Cancer: A Review

  2023influential citation
• Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications

  2023cites this paper
• Impact of delayed interval cytoreductive surgery on the survival of patients with advanced stage high-grade epithelial ovarian carcinoma

  2023cites this paper
• 3–4 Cycles versus 6 Cycles Neoadjuvant Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: Survival Is Not Determined by the Number of Neoadjuvant Chemotherapy Cycles

  2023cites this paper
• Prise en charge chirurgicale des cancers de l’ovaire de stade avancé après chimiothérapie néoadjuvante étude retrospective comparant la prise en charge chirurgicale après 3 cycles ou plus

  2023cites this paper
• Approaches to therapy for ovarian cancer yesterday, today, tomorrow

  2023cites this paper
• Optimal number of neoadjuvant chemotherapy cycles prior to interval debulking surgery in advanced epithelial ovarian cancer: a systematic review and meta-analysis of progression-free survival and overall survival

  2023cites this paper
• Laparoscopic versus open approach for interval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced epithelial ovarian cancer: a matched comparative study

  2023cites this paper
• Extra cycles of neoadjuvant chemotherapy before interval surgery for ovarian cancer: the more the merrier or too much of a good thing?

  2022cites this paper
• Multi-Omics Analysis of the Therapeutic Value of MAL2 Based on Data Mining in Human Cancers

  2022cites this paper
• Explainable Artificial Intelligence for Prediction of Complete Surgical Cytoreduction in Advanced-Stage Epithelial Ovarian Cancer

  2022cites this paper
• Complications associated with cytoreductive surgery for advanced ovarian cancer: Surgical timing and surmounting obstacles.

  2022cites this paper
• Neoadjuvant treatment in ovarian cancer: New perspectives, new challenges

  2022cites this paper
• Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction

  2022cites this paper
• Factors Predicting Surgical Effort Using Explainable Artificial Intelligence in Advanced Stage Epithelial Ovarian Cancer

  2022cites this paper
• INTERVAL DEBULKING SURGERY AFTER NEOADJUVANT CHEMOTHERAPY IN ADVANCED OVARIAN CANCER - RETROSPECTIVE STUDY COMPARING SURGERY AFTER 3 CYCLES OR MORE OF CHEMOTHERAPY.

  2022cites this paper
• Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients

  2022cites this paper
• Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer

  2022cites this paper
• An International Registry of Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

  2022cites this paper
• Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer

  2022cites this paper
• Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials

  2022cites this paper
• Anastomotic Leak in Ovarian Cancer Cytoreduction Surgery: A Systematic Review and Meta-Analysis

  2022cites this paper
• Cytoreductive Surgery With or Without HIPEC in the Management of Peritoneal Dissemination from Rare Histological Subtypes of Ovarian Cancer — a Retrospective Study by INDEPSO

  2022cites this paper
• Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study.

  2022cites this paper
• Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.

  2022cites this paper
• Subtyping of high grade serous ovarian carcinoma: histopathological and immunohistochemical approach

  2022cites this paper
• Impact of pattern of recurrence on post-relapse survival according to surgical timing in patients with advanced ovarian cancer

  2022cites this paper
• A Prediction Model for Optimal Primary Debulking Surgery Based on Preoperative Computed Tomography Scans and Clinical Factors in Patients With Advanced Ovarian Cancer: A Multicenter Retrospective Cohort Study

  2021cites this paper
• Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.

  2021cites this paper
• Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.

  2021cites this paper
• Optimal Strategies for Therapy and Screening

  2021cites this paper
• British Gynaecological Cancer Society (BGCS) Epithelial Ovarian / Fallopian Tube / Primary Peritoneal Cancer Guidelines: Recommendations for Practice 2017

  2021cites this paper
• A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer.

  2021cites this paper
• Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer

  2021cites this paper
• Ovarian Cancer: Primary Advanced and Recurrent Disease

  2021cites this paper
• Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients

  2021cites this paper
• Prolongation of Neoadjuvant Chemotherapy before Surgery: Seeking the Optimal Number of Cycles in Serous Ovarian Cancer

  2021cites this paper
• Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis.

  2021cites this paper
• Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening

  2021cites this paper
• Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.

  2021cites this paper
• Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review.

  2021cites this paper
• Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.

  2021cites this paper
• Interval debulking surgery for advanced ovarian cancer: when, how and why?

  2021cites this paper
• Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018.

  2021cites this paper
• Assessment of poor functional status and post-acute care needs following primary ovarian cancer debulking surgery

  2020cites this paper
• Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer

  2020cites this paper
• Comparing Laparotomy versus Robotic-Assisted Interval Debulking Surgery for Patients with Advanced Epithelial Ovarian Cancer Receiving Neoadjuvant Chemotherapy.

  2020cites this paper
• KRT7 promotes epithelial-mesenchymal transition in ovarian cancer via the TGF-β/Smad2/3 signaling pathway

  2020cites this paper
• Does preoperative CA-125 cutoff value and percent reduction in CA-125 levels correlate with surgical and survival outcome after neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer? – Our experience from a tertiary cancer institute

  2020influential citation
• The added value of CA125 normalization before interval debulking surgery to the chemotherapy response score for the prognostication of ovarian cancer patients receiving neoadjuvant chemotherapy for advanced disease

  2020cites this paper
• Identification of Ovarian Cancer Patients Most Likely to Achieve Chemotherapy Response Score 3 Following Neoadjuvant Chemotherapy: Development of a Predictive Nomogram

  2020cites this paper
• Evaluation of the feasibility of using weekly paclitaxel as neoadjuvant therapy in patients with epithelial ovarian cancer; a pre-post clinical trial

  2020cites this paper
• Neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer- a retrospective cohort study

  2020cites this paper
• A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.

  2020cites this paper
• Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study

  2020cites this paper
• Advanced stage ovarian cancer patients with neoadjuvant chemotherapy suffered worse recurrence free survival

  2020cites this paper
• Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer.

  2020cites this paper
• The Role Of Quaternary Cytoreduction In Relapsed Ovarian Cancer – A Systematic Review

  2020cites this paper
• Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial

  2020cites this paper
• Neoadjuvant Chemotherapy for Patients With Diaphragmatic Lesions: A Prognostic Postoperative Analysis

  2020cites this paper
• BRCA1/2 status and chemotherapy response score to tailor ovarian cancer surgery.

  2020cites this paper
• 30 Years of Experience in the Management of Stage III and IV Epithelial Ovarian Cancer: Impact of Surgical Strategies on Survival

  2020cites this paper
• Une approche radicale visant à obtenir une cytoréduction chirurgicale complète améliore la survie des patientes atteintes d’un cancer avancé de l’ovaire

  2020cites this paper
• Development of a decision aid for primary treatment of patients with advanced-stage ovarian cancer

  2020cites this paper
• Clinical significance of primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery in advanced ovarian cancer.

  2020cites this paper
• Neoadjuvant Versus Adjuvant Chemotherapy in Advanced Ovarian Carcinoma

  2020cites this paper
• Primary Debulking Surgery for Stage III Epithelial Ovarian Cancer Has a Better Outcome Than Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery

  2020cites this paper
• Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer

  2020cites this paper
• Intraperitoneal hyperthermic chemotherapy after cytoreduction in patients with peritoneal metastases from endometrial cancer. The next frontier?

  2020cites this paper
• Patterns of pathological response to neoadjuvant chemotherapy and its clinical implications in patients undergoing interval cytoreductive surgery for advanced serous epithelial ovarian cancer- A study by the Indian Network for Development of Peritoneal Surface Oncology (INDEPSO).

  2019cites this paper
• Comparison of Long-Term Survival Rates of Primary Surgery and Surgery After Neoadjuvant Chemotherapy in Ovarian Cancer

  2019cites this paper
• [Surgery for advanced stage ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].

  2019cites this paper
• Improving quality of care for patients with ovarian and endometrial cancer

  2019cites this paper
• Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: A French national multicenter study (FRANCOGYN).

  2019cites this paper
• Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer

  2019cites this paper
• A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer - A study by INDEPSO.

  2019cites this paper
• Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.

  2019cites this paper
• The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.

  2019cites this paper